Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Long-Term, Open-Label, Flexible-Dose, Extension Study Evaluating the Safety and Tolerability of Lu AA21004 (15 and 20 mg) in Subjects With Major Depressive Disorder

NCT01152996 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT01152996
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01152996 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Long-Term, Open-Label, Flexible-Dose, Extension Study Evaluating the Safety and Tolerability of Lu AA21004 (15 and 20 mg) in Subjects With Major Depressive Disorder
Lead sponsor
Takeda
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2010
Completion date
May 31, 2013
Enrollment
1,075 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

depressive disorder, major